Scynexis Inc (NASDAQ:SCYX) — Market Cap & Net Worth
Market Cap & Net Worth: Scynexis Inc (SCYX)
Scynexis Inc (NASDAQ:SCYX) has a market capitalization of $36.09 Million ($36.09 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23184 globally and #4990 in its home market, demonstrating a -8.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scynexis Inc's stock price $4.09 by its total outstanding shares 41965058 (41.97 Million). Review SCYX current and long-term liabilities to assess the company's total debt and financial obligations.
Scynexis Inc Market Cap History: 2015 to 2026
Scynexis Inc's market capitalization history from 2015 to 2026. Data shows change from $2.61 Billion to $171.64 Million (-23.04% CAGR).
Index Memberships
Scynexis Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #663 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2204 of 3165 |
Weight: Scynexis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scynexis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scynexis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.29x
Scynexis Inc's market cap is 1.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.34 Billion | $257.00K | -$29.99 Million | 5208.89x | N/A |
| 2017 | $973.59 Million | $257.00K | -$25.06 Million | 3788.29x | N/A |
| 2018 | $202.15 Million | $257.00K | -$12.47 Million | 786.56x | N/A |
| 2019 | $381.88 Million | $121.00K | -$53.71 Million | 3156.05x | N/A |
| 2020 | $321.03 Million | $12.05 Million | -$55.19 Million | 26.64x | N/A |
| 2021 | $255.99 Million | $13.16 Million | -$32.87 Million | 19.45x | N/A |
| 2022 | $65.47 Million | $5.09 Million | -$62.81 Million | 12.86x | N/A |
| 2023 | $93.58 Million | $140.14 Million | $67.04 Million | 0.67x | 1.40x |
| 2024 | $50.78 Million | $3.75 Million | -$21.29 Million | 13.56x | N/A |
| 2025 | $26.54 Million | $20.60 Million | -$8.61 Million | 1.29x | N/A |
Competitor Companies of SCYX by Market Capitalization
Companies near Scynexis Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Scynexis Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Scynexis Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Scynexis Inc's market cap moved from $2.61 Billion to $ 171.64 Million, with a yearly change of -23.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $171.64 Million | +546.74% |
| 2025 | $26.54 Million | -47.74% |
| 2024 | $50.78 Million | -45.74% |
| 2023 | $93.58 Million | +42.95% |
| 2022 | $65.47 Million | -74.43% |
| 2021 | $255.99 Million | -20.26% |
| 2020 | $321.03 Million | -15.93% |
| 2019 | $381.88 Million | +88.91% |
| 2018 | $202.15 Million | -79.24% |
| 2017 | $973.59 Million | -27.27% |
| 2016 | $1.34 Billion | -48.63% |
| 2015 | $2.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Scynexis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.09 Million USD |
| MoneyControl | $36.09 Million USD |
| MarketWatch | $36.09 Million USD |
| marketcap.company | $36.09 Million USD |
| Reuters | $36.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more